COVID-19 exhibits extensive patient-to-patient heterogeneity. To link immune response
variation to disease severity and outcome over time, we longitudinally assessed circulating …

The IMPACC cohort, composed of> 1,000 hospitalized COVID-19 participants, contains five
illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1 …

SARS-CoV-2 causes a spectrum of COVID-19 disease, the immunological basis of which
remains ill defined. We analyzed 85 SARS-CoV-2-infected individuals at acute and/or …

COVID-19 has become a global pandemic. Immune dysregulation has been implicated, but
immune responses remain poorly understood. We analyzed 71 COVID-19 patients …

With a rising incidence of COVID-19–associated morbidity and mortality worldwide, it is
critical to elucidate the innate and adaptive immune responses that drive disease severity …

SARS-CoV-2 has infected over 160 million and caused more than 3 million deaths to date.
Most individuals (> 80%) have mild symptoms and recover in the outpatient setting, but …

Summary Coronavirus disease 2019 (COVID-19) manifests with a range of severities, but
immune signatures of mild and severe disease are still not fully understood. Here, we use …

Abstract In coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection, the relationship between disease severity …

While immunologic correlates of COVID-19 have been widely reported, their associations
with post-acute sequelae of COVID-19 (PASC) remain less clear. Due to the wide array of …

We present an integrated analysis of the clinical measurements, immune cells, and plasma
multi-omics of 139 COVID-19 patients representing all levels of disease severity, from serial …